An extended analysis of the ODYSSEY OUTCOMES trial has confirmed alirocumab, a PCSK9 inhibitor that hit the medical market in 2015, reduces a patient’s total risk of nonfatal and fatal cardiovascular events after an acute coronary syndrome (ACS).

Archeologists have uncovered evidence of atherosclerosis in a handful of 500-year-old mummies from Greenland, Forbes reported.

Higher concentrations of troponin—even those that were within a “normal range”—signal increased odds of adverse outcomes among outpatients with stable chest pain, suggesting the biomarker test may improve risk stratification and inform management strategies for this common clinical scenario.

Research published in the Journal of the American Heart Association Jan. 13 has concluded administering PCSK9 inhibitors to acute MI patients ahead of ischemia can mitigate the potential negative neurological effects that come with treatment.

Measuring blood levels of vaspin could independently predict major adverse cardiac events (MACE) in patients who have suffered acute myocardial infarction (AMI), according to research published Jan. 16 in the Journal of the American Heart Association, potentially improving early risk stratification in heart attack survivors.

Sleeping less than six hours a night or experiencing poor-quality rest has been independently linked to an increased risk of subclinical multiterritory atherosclerosis, a team of Spanish researchers reported in the Journal of the American College of Cardiology Jan. 14.

A study published online in the American Journal of Epidemiology Jan. 14 suggests any physical movement, whether it’s short, long, intense or mild, counteracts the negative cardiovascular effects of sitting for long periods.

Elevated levels of cardiac troponin signal an increased risk of cardiovascular events even when the cause of that elevation is unknown, suggests a study published in the Journal of the American College of Cardiology.